CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 177 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 10 to 20 mg orallyAI-extracted
Key inclusion· 1
  • ✓Diagnosis of at least moderately severe generalized anxiety disorder (GAD)
Key exclusion· 7
  • ✕Serious suicide risk or psychiatric instability that would affect study participation
  • ✕Dementia
  • ✕Substance abuse, such as alcoholism, within 6 months prior to study entry
  • ✕Diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00105586
NCT00105586Phase 4Completed
CompareCT.gov

Pharmacotherapy of Late-Life Generalized Anxiety Disorder

University of Pittsburgh·interventional·Posted Mar 16, 2005·Updated May 8, 2017

In Brief

A Phase 4 clinical trial evaluating Escitalopram for Anxiety Disorders and Generalized Anxiety Disorder. Completed, enrolled 177 participants across 1 site.

Detailed Summary

This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorders, Generalized Anxiety Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 16, 2005
Enrollment StartDec 1, 2004
Primary CompletionJan 1, 2008
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 21.3 years ago

Interventions

Escitalopramdrug

Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.